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Abstract 
Background: Multimorbidity and musculoskeletal conditions create substantial burden for people and health sys-
tems. Quantifying the extent of co-occurring conditions is hampered by conceptual heterogeneity, imprecision and/
or indecision about how multimorbidity is defined. The purpose of this study is to examine the influence of different 
ways of operationalising multimorbidity on multimorbidity prevalence rates with a focus on working-age adults with 
musculoskeletal conditions. Weighted population prevalence rates of multimorbidity among working-age Austral-
ians were estimated using data from the National Health Survey. Two nominal thresholds (2+ or 3+ co-occurring 
conditions) and three operational definitions of multimorbidity (survey-, policy- and research-based) were examined. 
Using logistic regression, we estimated the association between the prevalence of multimorbidity among persons 
with musculoskeletal conditions compared to persons with non-musculoskeletal conditions for each definition and 
threshold combination.
Results: As few as 7.9% of working-age Australians have 2+ conditions using the research-based definition (95% CI 
7.4–8.5%), compared to estimates of 15.3% (95% CI 14.3–16.2%) and 61.5% (95% CI 60.3–62.7%). with the policy- and 
survey-based definitions, respectively. Depending on definition, with the 3+ threshold multimorbidity prevalence 
ranged from 2.1% (research) to 41.9% (survey). Among the sub-sample with musculoskeletal conditions, multimor-
bidity with the 2+ threshold ranged from 20.2 to 92.2%; and with 3+ threshold from 5.9 to 75.4%, again lowest with 
the research-definition and highest with the survey-definition. When compared to any other condition (i.e. non-
musculoskeletal conditions), all musculoskeletal conditions were positively associated with multimorbidity, regardless 
of definition or threshold.
Conclusions: Depending on definition and threshold, multimorbidity is either rare or endemic in working-age Aus-
tralians. Irrespective of definition, musculoskeletal conditions are a near-ubiquitous feature of multimorbidity.
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Background
Musculoskeletal conditions, such as arthritis, are highly 
prevalent throughout the world and create a substantial 
health burden for individuals, health systems and soci-
ety due to their clinical features, fluctuating nature and 
inherent complexity of treatment regimens [1–4]. Mus-
culoskeletal conditions are not exclusively a disease of 
old age, as almost one in five working-age people (aged 
18–64 years) have a musculoskeletal condition [5–7]. For 
working-aged people, musculoskeletal conditions can 
have substantial employment and financial impacts [8, 
9]. Furthermore, co-occurring conditions are increas-
ingly prevalent amongst those with musculoskeletal con-
ditions [5, 6, 10–14], and musculoskeletal conditions are 
common components of multimorbidity clusters [15, 
16]. Multimorbidity increases health expenditure [17], 
usage of health care services, polypharmacy and mortal-
ity rates, and reduces functional status and quality of life 
[18–23]. Therefore, it is important to consider multimor-
bidity when treating people with musculoskeletal con-
ditions [23]. Consequently, clinical and policy efforts to 
improve treatment of musculoskeletal conditions cannot 
be implemented without regard to the possible impacts 
of other conditions [12, 16–18, 24–26].
In addressing the issue of multiple co-occurring 
chronic conditions, a number of terms are used in the lit-
erature, including multimorbidity [11, 14], and comorbid-
ity [6, 14, 27]. Clinically, ‘multimorbidity’ conceptualises 
and treats all coexisting conditions as one distinct entity 
within an individual, with all conditions having equal 
importance [21]. ‘Comorbidity’ focuses on a single index 
condition and considers additional conditions in relation 
to their causality (consequence or coincidence) with, or 
on, this index condition [21].
Epidemiologically, ‘multimorbidity’ applies when esti-
mating the prevalence of co-occurring conditions among 
the wider population, and ‘comorbidity’ applies when 
estimating co-occurring conditions among populations 
with an index condition [28]. This distinction is impor-
tant because estimates that include those without any 
disease at all result in a lower multimorbidity prevalence, 
compared to disease-specific subpopulations where all 
individuals have an index condition by definition [6, 14]. 
When estimating how related a particular condition and 
multimorbidity are, the most relevant comparison group 
is a population with other types chronic conditions. For 
example, when determining the association between 
musculoskeletal conditions and multimorbidity, those 
with any condition other than a musculoskeletal con-
dition is the most relevant comparison group. This is 
because the presence of one condition increases risk of 
multimorbidity in disease-specific populations, due to 
shared life-style and biomedical disease risk factors, as 
well as medicines use [29] or induced diseases [30, 31], 
which increases the likelihood of developing another 
condition [32].
Despite its recognised importance (and cost), discus-
sions of multimorbidity are hampered by inconsistent 
conceptual and operational definitions of what consti-
tutes multimorbidity, making comparisons across studies 
problematic [16]. A fundamental difference is the nomi-
nal ‘multimorbidity threshold’ (i.e. the minimum number 
of conditions constituting multimorbidity). While the 
most common and intuitive threshold for multimorbid-
ity is at least two conditions (the ‘2+’ threshold), recent 
research recommends that in conjunction with this, a 
threshold of at least three conditions (‘3+’ threshold) 
should also be used to provide a more reliable estimate of 
multimorbidity [33].
Alongside issues of threshold, study comparability is 
further limited by the number of variants of ‘operational 
definitions’ of multimorbidity, which stipulate the condi-
tions counted in any pre-specified list used to estimate 
population levels of multimorbidity [33–36]. What is 
counted as a condition contributing to multimorbidity 
can be quite arbitrary. Unfortunately, there is no ‘gold 
standard’ as a reference point.
In addition to variations in inclusion of specific condi-
tions that constitute multimorbidity, the level of condi-
tion abstraction varies. Studies inconsistently combine 
clinically distinct conditions into broad umbrella cat-
egories (e.g. ‘musculoskeletal conditions’ [11], ‘joint dis-
ease’ [37] or ‘arthritis’ [5–7, 15], known as ‘lumping’), 
while others focus on single conditions, sometimes to 
the exclusion of others (e.g. ‘osteoarthritis’ [38], divorced 
from all other musculoskeletal conditions, known as 
‘splitting’). Lumping or splitting of conditions is poten-
tially problematic for identifying patterns in multimor-
bidity, particularly that which includes musculoskeletal 
conditions given their clinically (and socially) heteroge-
neous nature.
Another inherent difficulty in comparing multimor-
bidity studies is variation in the estimates themselves, 
which can be attributed to differences in the population 
selected for study. Estimates of population prevalence 
of multimorbidity are typically based on populations 
attending particular services or GP clinics [11, 39]. Such 
populations will naturally be skewed towards older and/
or less healthy people than within the wider population 
[40], potentially overestimating multimorbidity preva-
lence. Conversely, sample populations drawn from those 
currently employed in the workforce potentially skew 
towards those in better health, underestimating preva-
lence [15]. Reliable estimates of population prevalence of 
multimorbidity that include musculoskeletal conditions 
are particularly lacking and in an Australian context, 
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where research is limited to the elderly and/or patients 
consulting their general practitioner, or to healthier, cur-
rently-employed workplace-based samples [5, 6, 11, 13, 
15, 38, 41, 42].
To date, only one study has directly examined the influ-
ence of applying differing definitions of multimorbidity 
when estimating prevalence, and this study sampled from 
a general practice setting [39]. This direct comparison 
illustrates that the magnitude of multimorbidity preva-
lence varies significantly across the different nominal 
thresholds and operational definitions used [39]. How-
ever, the impact of thresholds and definitions has yet to 
been examined in the community-based population.
Due to these inconsistencies, it remains to be deter-
mined whether the prevalence of multimorbidity is uni-
form across different musculoskeletal populations, or if 
musculoskeletal conditions in general, or only particular 
subgroups of musculoskeletal conditions, are associated 
with increased prevalence of multimorbidity. Such infor-
mation may help identify common groups of multimor-
bidities and therefore potential target populations for 
interventions aimed at ameliorating the increased burden 
associated with multimorbidity.
We sought to identify the influence of various definitions 
and thresholds on multimorbidity prevalence and associa-
tion estimates. Specifically, this study estimates prevalence 
of, and association between, musculoskeletal and co-
occurring conditions, and evaluates the implications of the 
following differences in multimorbidity definitions:
a. Changing the minimum number (nominal threshold) 
of conditions that constitute multimorbidity (i.e. the 
2+ and 3+ condition thresholds);
b. Changing the range of chronic conditions included 
(operational definition) by examining three existing, 
pre-defined lists of conditions for operationalising 
multimorbidity, drawn from ‘survey-’ [43], ‘policy-’ 
[44] and ‘research-based’ [35] contexts; and
c. Changing the level of abstraction of conditions con-
sidered musculoskeletal by lumping and splitting the 
musculoskeletal sample population.
We use data from the Australian Bureau of Statistics’ 
National Health Survey 2007–08 [43], a representative 
population sample. To address a current gap in knowl-




We used cross-sectional data from the Australian Bureau 
of Statistics’ (ABS) National Health Survey 2007–08 
(NHS 2007–08) [43]. The population survey is a nation-
ally representative sample of 20,788 people from all Aus-
tralian states and territories and across all age groups. 
One person aged 18  years and over and one child were 
randomly selected from 15,800 private households 
across Australia to be surveyed. Interviews, covering a 
wide range of self-reported personal health information, 
were completed by the ABS with an adult and, where 
relevant, a child (following parent or guardian consent). 
The overall response rate for the NHS 2007–08 was 
91%. The collection of NHS data and participant obli-
gations and safeguards are governed by the Census and 
Statistics Act 1905 (Cth). Under the Act, participants are 
required to provide the information requested. The ABS 
is obliged by the Act to maintain the privacy of all infor-
mation provided. No information is released in a way that 
would enable an individual or household to be identified. 
Detailed information about sampling, survey design and 
questions asked is available elsewhere [43].
This study was granted exemption from ethics review 
by the La Trobe University Faculty of Health Sciences 
Faculty Ethics Review Committee due to negligible risk.
Sample
For the purpose of this study, the sample population 
was defined as working-age survey respondents (18–
64 years). The primary group of interest were those self-
reporting chronic musculoskeletal conditions, considered 
as a heterogeneous lumped group (i.e. ‘musculoskeletal 
conditions’), as well as split in homogenous subgroupings 
(e.g. ‘osteoarthritis’) at the most basic level of abstrac-
tion available within the data collected. The homogenous 
musculoskeletal subgroups were: osteoarthritis; inflam-
matory arthritis; other arthritis or arthropathies; soft tis-
sue disorders; back pain; gout; osteoporosis; and other 
musculoskeletal conditions (see Additional file  1: Table 
S1). We considered a musculoskeletal condition ‘chronic’ 
if it was: (1) current at the time of interview; and (2) 
reported as being present for six months or more.
Multimorbidity nominal thresholds and operational 
definitions
Two nominal multimorbidity thresholds (i.e. minimum 
of 2+ and 3+ conditions) were compared in this analy-
sis, alongside three different operational definitions (see 
Additional file 2: Table S2 for complete list of conditions 
included in each of the survey-, policy- and research-
based definitions; see Additional file  3 for glossary of 
terms). Within Additional file 2: Table S2, columns 2, 4, 
and 6 detail the actual conditions included in each defini-
tion, while columns 3 and 5 detail the condition groups at 
the abstracted level:
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  • Survey-based definition An open-ended definition, 
inclusive of all long-term conditions reported by 
respondents as part of the NHS 2007–08. This defi-
nition includes the presence of all current diagnoses 
(illnesses, injuries or disabilities) self-reported as hav-
ing been present for six months or more at the time 
of the interview, and were subsequently classified 
to 107 condition categories using ICD-10-AM (see 
Additional file  2: Table S2: column 2). Within this 
multimorbidity definition, injuries (such as fractures, 
amputations, nerve damage, and joint injury) and 
infections (such as HIV, hepatitis C, or tuberculosis) 
were included. These conditions were current and 
present for six months, which suggests they could be 
permanent or required prolonged rehabilitation or 
treatment.
  • Policy-based definition This definition included the 
chronic health conditions identified as Australian 
National Health Priority Areas (NHPAs) based on 
high population prevalence and high impact on indi-
viduals and the health system [44]. These include: 
musculoskeletal conditions, diabetes, cancer, cardio-
vascular disease, asthma, chronic obstructive pulmo-
nary disease, and mental health disorders (see Addi-
tional file  2: Table S2: columns 3 and 4). Although 
classified as NHPAs, obesity and injury prevention/
control were excluded from this analysis. Obesity 
was excluded on the basis that there is disagreement 
that it is a disease [45, 46], and its ineligibility for 
Medicare-based coverage on its own [47]: further-
more, obesity data was available for only a sub-set 
of respondents. Injury prevention/control was not 
included as these are not diseases per se. Data on 
dementia was subsumed within an umbrella category 
of conditions included in the mental health disorder 
category (symptoms and signs involving cognition, 
perceptions, emotional state and behaviour), how-
ever, dementia is uncommon among the working-age 
population [48].
  • Research-based definition The definition was based 
on a recent literature review by Diederichs et  al. 
[35], which recommends inclusion of the follow-
ing 11 conditions in multimorbidity studies: can-
cer, diabetes mellitus, depression, hypertension, 
myocardial infarction, chronic ischemic heart dis-
ease, heart arrhythmias, heart insufficiency, stroke, 
chronic obstructive pulmonary disease, and arthri-
tis (see Additional file 2: Table S2: columns 5 and 6). 
This definition was modified slightly for this study 
by combining myocardial infarction and chronic 
ischemic heart disease, as it was not possible to sepa-
rate the two in the available data. Notably, unlike the 
other two definitions, this definition excludes non-
arthritis musculoskeletal conditions. As such, the 
presence of soft tissue disorders, back pain, osteopo-
rosis, and other musculoskeletal conditions were not 
counted towards multimorbidity with this definition.
As above, for all definitions, the selected conditions 
were only included if they were chronic; that is, they were 
both current and present for six months or more.
Analyses
Utilising the NHS 2007–08, confidentialised unit record 
file (CURF) data, weighted population prevalence and 
associations taking into account survey design, were 
estimated with the jack-knife method applying the rep-
licate weights provided by the ABS [49]. Prevalence was 
estimated for each definition–threshold combination 
to determine the extent of multimorbidity among the 
working-age population with or without musculoskeletal 
conditions. Specifically, for each multimorbidity defini-
tion–threshold combination we estimated the:
1. Proportion of respondents with multimorbidity, from 
the total working-age population. This is represented 
by C/A in Fig. 1;
2. Proportion of respondents with multimorbidity that 
includes at least one musculoskeletal condition, from 
the total working-age population. This is represented 
by E/A in Fig. 1;
3. Proportion of respondents with a musculoskeletal 
condition, from the multimorbidity subsample. This 
is represented by E/C in Fig. 1; and
Fig. 1 Illustration of broad populations of interest
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4. Proportion of co-occurring conditions among the 
working-age population with any (lumped), and spe-
cific (split) musculoskeletal condition(s). This is rep-
resented by E/D in Fig. 1.
Finally, we used logistic regression to identify the 
odds of multimorbidity in persons with musculoskeletal 
conditions, compared with the odds of multimorbidity 
occurring in persons with non-musculoskeletal condi-
tions, whilst taking into account any age and gender dif-
ferences between each group. The reference group was 
the working-age population with any non-musculoskel-
etal conditions (i.e. B minus D in Fig. 1) included in the 
particular multimorbidity operational definition forming 
the analysis. As above, for each operational definition 
used, we compared estimates obtained when the mini-
mum number of diagnoses (i.e. nominal threshold) that 
constitute multimorbidity/comorbidity varied (2+ and 
3+ conditions) [33]. Odds ratios and confidence inter-
vals were estimated using logistic regression, adjusting 
for age and gender. All statistical analyses were per-
formed using Stata (release 10.1, College Station, TX, 
USA).
Results
Weighted population prevalence estimates
Of the 20,788 NHS 2007–08 sample, 12,604 survey 
respondents were of working-age; of these, 4555 self-
reported at least one current chronic musculoskeletal 
condition. Compared to those without musculoskeletal 
conditions, working-age people with musculoskeletal 
conditions were more likely to be older (43.7 vs 20.5%), 
born in Australia (74.7 vs 69.6%), and report the pres-
ence of three or more of the following disease risk fac-
tors of obesity; high blood pressure; osteoporosis; high 
cholesterol; high blood sugar; risky level of alcohol con-
sumption; current smoker; insufficient vegetable intake; 
insufficient fruit intake; and sedentary lifestyle (42.5 vs 
33.9%). However, they were less likely to live in a major 
city (65.1 vs 72.05%), work full-time (50.3 vs 58.9%) 
or possess an undergraduate degree (19.8 vs 24.2%) 
(Table 1).
Multimorbidity in the total working‑age population (C/A; 
Fig. 2)
Using the survey-based definition, the proportion of the 
Australian working-age population (n = 12,604) consid-
ered multimorbid was 61.5% (95% confidence interval 
[CI] 60.3–63.7%) at the 2+ condition threshold (Table 2). 
Using the policy-based definition, multimorbidity preva-
lence was 15.3% (95% CI 14.3–16.2%). Multimorbidity 
prevalence was lowest with the research-based definition: 
7.9% (95% CI 7.4–8.5%). Notably, 1034 participants with 
non-arthritis musculoskeletal conditions are excluded 
from the multimorbidity count with this research-based 
definition. Using the 3+ condition threshold, multi-
morbidity prevalence rates decreased to 41.9% (95% CI 
40.6–43.1%); 4.2% (95% CI 3.7–4.7%); and 2.1% (95% CI 
1.8–2.5%) for the survey-, policy- and research-based 
definitions respectively (Table 2).
Working‑age population with multimorbidity that includes 
a musculoskeletal condition (E/A; Fig. 2)
Within the working-age population, the weighted popu-
lation prevalence of multimorbidity involving a mus-
culoskeletal condition varied dramatically between 
definitions. These estimates ranged between 31.1% 
(95% CI 29.9–32.3%) with the survey definition with 2+ 
threshold, to as few as 2.0% (95% CI 1.6–2.3%) with the 
research definition with 3+ threshold.
Lumped musculoskeletal conditions among working‑age 
population with multimorbidity (E/C; Fig. 2)
Regardless of threshold, using either the policy- or 
research-based definition, the vast majority of those 
with multimorbidity have at least one musculoskel-
etal condition [84.8% (95% CI 83.0–86.5%) and 86.0% 
(95% CI 83.4–88.5%)] (see Table  2). A lower propor-
tion [50.6% (95% CI 49.1–52.1%)] of those captured 
by the survey-based definition have multimorbidity 
that involves musculoskeletal conditions. When a 3+ 
condition threshold was used, the proportion of those 
with a musculoskeletal condition within the popula-
tions with survey-, policy- and research-defined mul-
timorbidity rose to 60.7% (95% CI 58.9–62.5%); 91.8% 
(95% CI 88.4–95.2%) and 93.5% (95% CI 90.4–96.5%) 
respectively.
Comorbidities among the working‑age population 
with any lumped musculoskeletal condition (E/D; Fig. 2)
Among working-age people with at least one muscu-
loskeletal condition (n  =  4555), the prevalence of co-
occurring conditions was higher than in the working-age 
population without musculoskeletal conditions; how-
ever, prevalence varied widely with the different defini-
tions and thresholds used (Table 3). Among working-age 
people with musculoskeletal conditions, the proportion 
at the 2+ threshold (where one condition was a mus-
culoskeletal condition) was 92.2% (95% CI 90.9–93.3%; 
survey-based definition); 38.3% (95% CI 36.5–40.1%; 
policy-based) and 20.2% (95% CI 18.9–21.6%; research-
based). Using a 3+ threshold (where one condition is a 
musculoskeletal condition), prevalence of comorbidity 
was 75.4% (95% CI 73.6–77.0%); 11.4% (95% CI 10.1–
12.8%); 5.9% (95% CI 4.9–7.0%) for the same definitions, 
respectively.
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Comorbidities among the working‑age population 
with specific split musculoskeletal conditions (sub‑groups 
within E/D; Fig. 2)
For the survey-based definition, when the level of 
abstraction is split into specific musculoskeletal sub-
groups, the subgroups with highest multimorbidity 
prevalence with 2+ threshold were osteoporosis (99.0%); 
osteoarthritis (98.5%) and inflammatory arthritis (98.2%), 
while the lowest prevalence rates were observed for gout 
(90.9%) and back pain (91.7%) (Table 3). With the policy-
based definition, the musculoskeletal subgroups with 
highest prevalence with 2+ threshold were inflammatory 
Table 1 Demographic characteristics of working-age (18–64 years) respondents; and the subsets with and without mus-
culoskeletal conditions (MSK)
All estimates adjusted for survey design
a Disease risk factors: obesity; high blood pressure; osteoporosis; high cholesterol; high blood sugar; risky level of alcohol consumption; current smoker; insufficient 
vegetable intake; insufficient fruit intake; and sedentary lifestyle
Characteristics Total % (n = 12,604) With MSK % (n = 4555) No MSK % (n = 8049) P value
Age group <0.01
 18–34 37.1 21.5 45.0
 35–49 34.6 34.8 34.5
 50–64 28.3 43.7 20.5
Gender 0.82
 Female 50.1 50.3 50.0
Place of birth <0.01
 Australia 71.3 74.7 69.6
Household equivalised income quintile <0.01
 First quintile 9.6 13.6 7.5
 Second quintile 14.4 14.9 14.1
 Third quintile 19.3 19.6 19.2
 Fourth quintile 20.8 19.1 21.6
 Fifth quintile 20.6 17.9 22.0
 Not stated 15.3 14.8 15.6
Education level <0.01
 Year 12 or less 43.5 43.3 43.6
 Diploma/certificate 33.8 36.9 32.2
 Bachelor or higher 22.8 19.8 24.2
Hours worked <0.01
 No hours 22.3 28.9 19.0
 1–34 h 21.7 20.8 22.2
 35+ h 56.0 50.3 58.9
Region of Australia <0.01
 Major cities 69.7 65.1 72.0
 Inner regional 19.9 23.1 18.3
 Other areas 10.4 11.8 9.7
Household structure <0.01
 Couple and child(ren) 43.3 39.7 45.1
 Parent and child(ren) 8.3 7.9 8.5
 Couple only 23.0 27.5 20.8
 Single person 10.9 13.2 9.7
 Other 14.5 11.7 15.9
Number of disease risk factorsa <0.01
 None 6.1 5.2 6.6
 1 24.5 22.6 25.5
 2 32.6 29.8 34.0
 3 or more 36.8 42.5 33.9
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Fig. 2 Overlap between populations with musculoskeletal conditions and multimorbidity as defined by each definition and threshold. a Total 
working-age sample population; b sub-sample with at least one condition; c sub-sample with multimorbidity; d sub-sample with any musculoskel-
etal condition; e musculoskeletal sub-sample considered multimorbid
Table 2 Working-age population prevalence of  (1) multimorbidity, (2) any musculoskeletal condition (MSK) and  multi-
morbidity, and (3) MSK among those with multimorbidity
a All prevalence estimates are based on the total Australian working-age population (ages 18-64 years) by taking the NHS survey design weightings into account, 
unless otherwise specified
b Survey-based: multimorbidity defined as including any two or more of the possible conditions measured in the Australian National Health Survey that were 
reported as being present for 6 months or more
c Policy-based: multimorbidity defined as including two or more of any of the restricted classes of morbidities based on Australian National Health Priority Areas 
being present for 6 months or more: musculoskeletal conditions, diabetes, cancer, cardiovascular disease, asthma, chronic obstructive pulmonary disease, mental 
health
d Research-based: 11 specific conditions being present for 6 months or more, based on a literature review conducted by Diederichs et al. [35], cancer, diabetes 
mellitus, depression, hypertension, myocardial infarction, chronic ischemic heart disease, heart arrhythmias, heart insufficiency, stroke, chronic obstructive pulmonary 
disease, and arthritis
Population description Prevalence  % (95% CIs)a
Condition threshold Survey‑based definitionb Policy‑based definitionc Research‑based definitiond
1. Multimorbidity among the working-
age population (i.e. C/A; Fig. 2) 
(n = 12,604)
2+ 61.5 (60.3, 62.7) 15.3 (14.3, 16.2) 7.9 (7.4, 8.5)
3+ 41.9 (40.6, 43.1) 4.2 (3.7, 4.7) 2.1 (1.8, 2.5)
2. Multimorbidity that includes at 
least one MSK among the working-
age population (i.e. E/A; Fig. 2) 
(n = 12,604)
2+ 31.1 (29.9, 32.3) 12.9 (12.1, 13.7) 6.8 (6.3, 7.4)
3+ 25.4 (24.3, 26.5) 3.8 (3.4, 4.3) 2.0 (1.6, 2.3)
3. MSK among the working-age sub-
sample with multimorbidity (i.e. E/C; 
Fig. 2) (n = varies for each multimor-
bidity definition)
2+ 50.6 (49.1, 52.1) 84.8 (83.0, 86.5) 86.0 (83.4, 88.5)
3+ 60.7 (58.9, 62.5) 91.8 (88.4, 95.2) 93.5 (90.4, 96.5)
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arthritis (53.1%), osteoporosis (50.4%), soft tissue con-
ditions (46.9%) and osteoarthritis (46.1%) and lowest 
prevalence again were with gout and back pain (37.8 and 
39.8%, respectively). Prevalence (with 2+ threshold) was 
also highest among those with inflammatory arthritis 
(45.3%); osteoarthritis (40.4%) and gout (33.9%) using the 
research-based definition and lowest again for those with 
back pain (15.8%) and this time, those with other mus-
culoskeletal conditions not elsewhere described (22.7%). 
Increasing to the 3+ condition threshold did not sub-
stantially alter the musculoskeletal subgroups with high-
est and lowest prevalence of multimorbidity; however, 
rates were reduced slightly.
Associations between musculoskeletal conditions 
and multimorbidity
After adjustment for age and gender, the odds of mul-
timorbidity were greater in respondents with mus-
culoskeletal conditions than those with any of the 
non-musculoskeletal conditions included in each defi-
nition of multimorbidity assessed. However, there were 
variations in the strength of these associations, with the 
strongest associations seen for the survey-based defini-
tion [adjusted Odds Ratio (aOR) 6.7 (95% CI 5.6–8.1)]; 
and weakest for the policy-based definition [aOR 1.5 
(95% CI 1.2–2.0)]. As such, the strength of the associa-
tions seems related to the prevalence produced by the 
definition; strongest associations are seen for definitions 
producing the greatest prevalence of multimorbidity. The 
magnitude in the difference between these associations 
produced by each definition was greater with the two 
condition multimorbidity threshold (as opposed to the 
three condition threshold where the confidence intervals 
of the effect estimates often overlapped). This pattern of 
results also applied when examining the specific muscu-
loskeletal conditions. For example, the odds of survey-
based multimorbidity among persons with osteoarthritis 
was 30.0 times that of persons with any other non-mus-
culoskeletal condition comprising the survey definition 
(95% CI 15.2–59.2); while the comparable associations 
for the policy and research definitions were aOR 3.7 (95% 
CI 2.7–4.9) and aOR 3.3 (95% CI 2.5–4.5) (Table 4).
Discussion
We found that within the Australian working-age popu-
lation, prevalence estimates for multimorbidity varied 
greatly from 61.5% in the unrestricted survey-based 
definition (2+ threshold) to 15.3% (policy) and 7.9% 
Table 3 Working-age population prevalence of  multimorbidity among  those with  musculoskeletal conditions (MSK) 
(lumped and split into subgroups)
a See footnote of Table 2 for details of each multimorbidity definition
b All prevalence estimates representative of the whole of the Australian working-age population (ages 18–64 years) by taking the NHS survey design weightings into 
account, unless otherwise specified
Multimorbidity prevalence  % (95% CIs)
Survey‑based definitiona Policy‑based definitiona Research‑based definitiona
1. Prevalence of two or more co-occurring conditions (2+ threshold)b
Any MSK (n = 4555) 92.2 (90.9, 93.3) 38.3 (36.5, 40.1) 20.2 (18.9, 21.6)
 Osteoarthritis 98.5 (97.3, 99.2) 46.1 (41.3, 51.1) 40.4 (36.2, 44.8)
 Inflammatory arthritis 98.2 (90.5, 99.7) 53.1 (45.2, 61.0) 45.3 (37.3, 53.5)
 Other arthritis 95.0 (93.2, 96.4) 41.9 (38.1, 45.8) 27.2 (23.4, 31.2)
 Gout 90.9 (87.0, 93.7) 37.8 (32.8, 43.1) 33.9 (29.1, 39.0)
 Other musculoskeletal 95.6 (88.0, 98.5) 41.4 (28.0, 56.3) 22.7 (12.4, 37.8)
 Back pain 91.7 (90.0, 93.2) 39.8 (37.6, 42.0) 15.8 (14.0, 17.8)
 Soft tissue conditions 95.9 (91.3, 98.1) 46.9 (40.3, 53.6) 25.4 (20.1, 31.5)
 Osteoporosis 99.0 (96.0, 99.8) 50.4 (42.1, 58.7) 27.4 (20.3, 36.0)
2. Prevalence of three or more co-occurring conditions (3+ threshold)
Any MSK 75.4 (73.6, 77.0) 11.4 (10.1, 12.8) 5.9 (4.9, 7.0)
 Osteoarthritis 90.7 (88.0, 92.9) 16.4 (13.2, 20.2) 11.3 (8.6, 14.7)
 Inflammatory arthritis 88.0 (79.7, 93.2) 23.0 (17.1, 30.2) 14.7 (9.5, 22.0)
 Other arthritis 81.8 (78.5, 84.7) 14.7 (12.0, 17.8) 8.5 (5.8, 12.3)
 Gout 77.3 (72.4, 81.6) 10.6 (8.1, 13.7) 10.4 (7.8, 13.7)
 Other musculoskeletal 79.0 (66.8, 87.6) 11.8 (6.0, 22.0) 6.5 (2.9, 13.8)
 Back pain 76.0 (73.4, 78.3) 11.7 (10.0, 13.7) 5.1 (4.2, 6.4)
 Soft tissue conditions 82.9 (76.4, 87.9) 18.07 (13.5, 23.8) 7.6 (5.0, 11.4)
 Osteoporosis 89.1 (81.8, 93.7) 17.3 (13.1, 22.5) 9.0 (5.1, 15.5)
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(research) definitions, despite each purporting to meas-
ure the same phenomenon.
This finding is consistent with other research into the 
impact of multimorbidity definitions [39, 50] and thresh-
olds [39, 51] although Fortin et al. [50] examined preva-
lence in different source populations making it difficult 
to determine if the differences in prevalence estimate was 
due to the different definitions or the underlying burden 
of disease in the populations assessed. Our estimates 
from a nationally-representative population sample 
are similar to those reported in a study of an Australian 
population [39, 51] sampled from general practice, with 
conditions identified via doctor diagnosis and different 
criteria for chronicity.
Our study comprehensively estimates the extent of 
multimorbidity among the musculoskeletal population—
a population with clinical and policy relevance [44]. 
Regardless of the definition or threshold, musculoskel-
etal conditions are a common component of multimor-
bidity. Most working-age adults who met the policy and 
research definition of multimorbid had a musculoskeletal 
condition. This is an important finding because the inclu-
sion of musculoskeletal conditions within multimorbidity 
research has been inconsistent.
Musculoskeletal conditions are a clinically heterogene-
ous group and it is plausible that the prevalence of mul-
timorbidity might vary for sub-types of musculoskeletal 
conditions with each definition. The subgroups with the 
highest prevalence of multimorbidity were typically oste-
oporosis, osteoarthritis and inflammatory arthritis.
There is a lack of conceptual clarity for multimorbid-
ity as a construct, as evidenced by the large number of 
multimorbidity definitions already in use and the wide-
ranging estimates of prevalence they generate. Despite 
each definition investigated here purporting to measure 
multimorbidity prevalence estimates varied greatly, dem-
onstrating the elastic nature of multimorbidity as a con-
cept. Consistency of definition is critical for comparing 
the burden of multimorbidity between and within popu-
lations, and changes over time. Despite the potential ben-
efits of a consistent definition of multimorbidity, it may 
actually require more than a single definition, so long as 
the implications of such differences are understood. This 
will enable definitions to be fit for purpose, relevant to 
specific contexts and allow consideration of the relevant 
multimorbidity features.
There are advantages and disadvantages for using 
each of the definitions examined here. The survey-based 
Table 4 Adjusted associations between multimorbidity and musculoskeletal conditions
a  Association estimates based on comparison with respondents with any of the non-musculoskeletal conditions in each definition
b  Adjusted for age and gender
c  See footnote of Table 2 for details definitions of multimorbidity used in analyses
Multimorbidity OR (95% CI)a, b
Survey‑based definitionc Policy‑based definitionc Research‑based definitionc
1. Two or more co-occurring conditions (2+ threshold)
Musculoskeletal 6.7 (5.6, 8.1) 3.0 (2.6, 3.5) 1.5 (1.2, 2.0)
Osteoarthritis 30.0 (15.2, 59.2) 3.7 (2.7, 4.9) 3.3 (2.5, 4.5)
Inflammatory arthritis 26.1 (0.7, 1035.2) 5.0 (3.3, 7.7) 4.4 (2.9, 6.7)
Other arthritis 10.5 (7.4, 15.1) 3.4 (2.8, 4.2) 2.1 (1.5, 2.9)
Gout 5.7 (3.7, 8.7) 2.8 (2.1, 3.7) 2.7 (2.0, 3.8)
Other musculoskeletal 13.3 (3.9, 45.7) 3.5 (1.9, 6.6) 1.8 (0.8, 3.9)
Back pain 6.9 (5.5, 8.6) 3.3 (2.8, 4.0) 1.3 (1.0, 1.6)
Soft tissue conditions 12.3 (5.4, 28.1) 4.0 (2.9, 5.4) 1.9 (1.3, 2.8)
Osteoporosis 40.4 (5.6, 291.1) 4.3 (3.0, 6.2) 1.9 (1.1, 3.1)
2. Three or more co-occurring conditions (3+ threshold)
Musculoskeletal 5.6 (4.9, 6.3) 4.7 (2.9, 7.5) 3.6 (2.1, 6.0)
Osteoarthritis 14.2 (10.5, 19.3) 7.2 (3.7, 13.8) 5.7 (3.4, 9.4)
Inflammatory arthritis 11.7 (6.0, 22.7) 11.2 (4.9, 25.9) 8.0 (3.8, 17.0)
Other arthritis 8.0 (6.3, 10.1) 6.1 (3.4, 10.9) 4.9 (2.4, 10.3)
Gout 6.3 (4.7, 8.3) 3.8 (2.0, 6.9) 5.1 (2.9, 9.0)
Other musculoskeletal 7.3 (4.0, 13.2) 4.8 (1.7, 13.4) 4.3 (1.7, 11.3)
Back pain 6.3 (5.4, 7.4) 5.1 (3.1, 8.3) 3.7 (2.2, 6.2)
Soft tissue conditions 8.3 (5.7, 12.1) 7.2 (4.0, 13.2) 4.4 (2.0, 9.9)
Osteoporosis 10.7 (5.7, 20.0) 6.8 (3.0, 15.2) 4.9 (1.9, 12.9)
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definition includes all chronic conditions self-reported 
by respondents and is therefore a comprehensive indi-
cation of what the respondents themselves consider 
as being co-occurring conditions. However, some may 
not be generally considered medical conditions (e.g. 
astigmatism) or may be conditions, that while chronic, 
may in some cases manifest themselves episodically or 
infrequently (e.g. migraines or asthma) and/or may not 
require medications to treat or manage (e.g. certain inju-
ries). Nonetheless, these conditions may be important 
for understanding multimorbidity [52]. However, the 
extremely high prevalence rates derived by the survey 
definition over emphasises the problem because it cap-
tures almost everyone and everything. This renders the 
utility of the survey definition as an indicator question-
able, as multimorbidity reaches endemic proportions, 
but more often than not will have questionable clinical 
relevance. However, the substantially higher prevalence 
derived from the survey definition highlights that the pol-
icy and research definitions do not capture the breadth 
of multimorbidity experienced within the working-age 
population. Previous research suggests the expression 
of multimorbidity is different in this younger popula-
tion [53]. Further research may need to be conducted 
to identify other clinically important (such as epilepsy) 
and common chronic conditions specific to working-age 
adults with multimorbidity, which are currently not cap-
tured by either the policy or research definitions.
The policy definition counts conditions identified as 
NHPAs for Australia [44]. This restricted inclusion of 
conditions, results in lower prevalence estimates, and 
more clinically relevant multimorbidity than that derived 
by the survey definition. However, the policy definition 
uses a level of highly-abstracted diagnosis. For example, 
a person with depression and comorbid anxiety would 
be attributed with just one condition (‘mental health’) 
using the policy definition. This creates a case of severe 
lumping and under-estimation, particularly for muscu-
loskeletal and mental health conditions. However, it may 
be appropriate to group related conditions when self-
reporting respondents may not be expected always to be 
familiar with medical terminology. For example, some 
individuals may not recognise their condition as specifi-
cally ‘ischemic heart disease’ or ‘myocardial infarction’, 
however, they may nominate they have these conditions 
when an umbrella term is used, such as ‘heart diseases’ 
[35]. As NHS 2007–08 data relied on self-report, the 
abstracted (lumped level) of conditions for the policy def-
inition is arguably more appropriate.
The research definition is restricted to conditions that 
are burdensome to individuals and is informed by a lit-
erature review of research [35]. However, in contrast to 
the policy definition, the research definition appears 
arbitrary about the range and level of abstraction of con-
ditions included, which may lead to both under and over 
-estimation of multimorbidity. For example, although 
depression is included in the research definition, all other 
mental health conditions are excluded, potentially con-
tributing to under-estimation of multimorbidity. Simi-
larly, although all arthritis conditions are included as an 
umbrella category, osteoporosis, back pain, soft tissue 
and other musculoskeletal conditions are excluded. In 
the context of this paper, the omission of non-arthritis 
musculoskeletal conditions is problematic, as the spe-
cific index condition (a musculoskeletal condition) will 
not be uniformly counted (or not counted), and there for 
result in bias in both prevalence estimates and measures 
of association. As a consequence lower multimorbidity 
prevalence rates are observed within these non-arthritis 
musculoskeletal subgroups. For example, those with an 
excluded musculoskeletal condition, such as osteoporo-
sis, would actually have (at least) three conditions to be 
considered multimorbid using the 2+ threshold with this 
research definition. Furthermore, the research definition 
is highly skewed to heart and cardiovascular diseases; 
with six specific forms of cardiovascular disease each 
counted individually towards multimorbidity, poten-
tially contributing to over-estimation. The definition we 
use here is slightly modified from that recommended by 
Diederichs et  al. [35], due to myocardial infarction and 
chronic ischemic heart disease being combined within 
the NHS 2007–08 data, so it counts five rather than six of 
these cardiovascular diseases.
As with previous studies, we have shown that the nomi-
nal threshold of the number of conditions contributing to 
multimorbidity matters when estimating prevalence and 
association, i.e. there is lower prevalence with increased 
threshold [39, 51]. There is a close relationship between 
prevalence estimates from a 2+ and 3+ thresholds of 
multimorbidity operationalised with simple condition-
counts [54]. Where the prevalence estimate for a 2+ 
threshold is known, the 3+ threshold can be estimated 
and vice versa [54]. However, knowing that this rela-
tionship exists does not guide the appropriate nominal 
threshold to use with a particular operational definition of 
multimorbidity. It has been suggested that the 3+ thresh-
old should be called ‘complex morbidity’ (defined as the 
co-occurrence of three or more chronic conditions affect-
ing three or more different body systems within one per-
son without defining an index chronic condition) [39]. In 
our study, the presence of three or more conditions when 
using the research and policy definitions may be sugges-
tive of ‘complex morbidity’. In contrast, due to the inclu-
sive nature of the survey definition, it would seem unlikely 
that the 3+ threshold is indicative of ‘complex multimor-
bidity’. Rather, with the 3+ threshold, multimorbidity with 
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the survey definition resembles multimorbidity derived 
from the research or policy definition with the 2+ thresh-
old. Therefore, we suggest that with inclusive (open list) 
definitions like the survey-definition the 3+ threshold 
may be more appropriate than the 2+ threshold, particu-
larly when comparing rates with studies using restrictive 
operational definitions such as the research or policy defi-
nition. Within multimorbidity operational definitions the 
inclusion of obesity, hypertension and hyperlipidaemia is 
inconsistent, reflecting broader debate around the status 
of these conditions that are sometimes considered modifi-
able risk factors for diseases or diseases in their own right 
[45–47]. We could not include obesity, although it is an 
Australian NHPA [46], because consistent data for BMI 
calculations was not collected. Further research is needed 
to better understand the appropriate threshold to use 
when definitions count these highly prevalent conditions 
towards multimorbidity.
Strengths of this study are use of Australian data that is 
population-based, community dwelling and of working 
aged adults. This avoids the limitations of clinical, con-
venience or opportunistic samples and fills the knowledge 
gap associated with sampling elderly populations or sam-
pling specific forms of arthritis populations [5, 6, 11, 15, 
38, 41, 42]. Furthermore, by conducting exploratory anal-
yses within the same population we are able to identify 
the variations in estimates attributable to the operational 
definitions and nominal thresholds used and not to differ-
ences in geographical setting, recruitment and data col-
lection methods. However, this analysis also has a number 
of limitations. As the sample was drawn from community 
dwelling populations and did not include people living 
in care facilities or hospitalised patients a selection bias 
towards sampling healthier respondents is plausible. Fur-
thermore, as the data is based on self-reported conditions, 
this information could be subject to recall bias. None of 
the definitions were weighted according to the severity 
of condition. While a number of operational definitions 
weight condition severity [55–60], there is little evidence 
that they are more effective in predicting outcomes such 
as mortality or health care utilisation compared to the 
simpler disease counts [34]. Additionally, although over-
all ratings of quality of life and pain were reported by 
each individual surveyed within the NHS 2007–08, it is 
not possible to apply a weighting to a specific condition. 
Therefore, in the context of multiple chronic conditions, it 
is appropriate that we used simple disease counts to esti-
mate population prevalence of multimorbidity.
Conclusion
We identified that among the Australian community 
dwelling, working-age population, depending on thresh-
old and definition used, multimorbidity is either a rare or 
endemic phenomenon. Regardless of definition, muscu-
loskeletal conditions are a common component of mul-
timorbidity, raising uncertainty for prevalence estimates 
which are limited to some forms of arthritis. There is a 
need to better understand multimorbidity that includes 
musculoskeletal conditions, in order to estimate burden 
to individuals and to prioritise prevention and treatment 
efforts. A next step includes determining forms of muscu-
loskeletal conditions for which the health and healthcare 
burden are exacerbated in the presence of multimorbidity.
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